

University of Massachusetts Medical School

eScholarship@UMMS

---

UMass Center for Clinical and Translational  
Science Research Retreat

2017 UMass Center for Clinical and  
Translational Science Research Retreat

---

May 16th, 1:45 PM

## Resident and Facility-level Correlations of Long-term Opioid Use in United States Nursing Homes

Jacob N. Hunnicutt

*University of Massachusetts Medical School*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: [https://escholarship.umassmed.edu/cts\\_retreat](https://escholarship.umassmed.edu/cts_retreat)



Part of the [Geriatrics Commons](#), [Health Services Administration Commons](#), [Pharmacy and Pharmaceutical Sciences Commons](#), and the [Translational Medical Research Commons](#)

---

### Repository Citation

Hunnicutt JN, Ulbricht CM, Hume A, Lapane KL. (2017). Resident and Facility-level Correlations of Long-term Opioid Use in United States Nursing Homes. UMass Center for Clinical and Translational Science Research Retreat. <https://doi.org/10.13028/maff-yb64>. Retrieved from [https://escholarship.umassmed.edu/cts\\_retreat/2017/posters/39](https://escholarship.umassmed.edu/cts_retreat/2017/posters/39)

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](#).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

## RESIDENT AND FACILITY-LEVEL CORRELATIONS OF LONG-TERM OPIOID USE IN UNITED STATES NURSING HOMES

Jacob N. Hunnicutt, MPH<sup>1</sup>; Christine Ulbricht, PhD<sup>1</sup>; Anne Hume, PharmD<sup>2</sup>; Kate Lapane, PhD<sup>1</sup>  
<sup>1</sup>University of Massachusetts Medical School; <sup>2</sup>University of Rhode Island, Kingston, RI

**Background:** There is limited information on the prevalence and multilevel risk factors of long-term opioid use in older nursing home residents despite their high burden of pain and vulnerability to adverse drug events.

**Objectives:** To estimate the prevalence and correlates of long-term opioid use in United States (US) nursing homes.

**Methods:** We used comprehensive administrative/claims data (Minimum Data Set 3.0; Medicare Part D) from 2012 to conduct a cross-sectional study of 369,180 long-stay nursing home residents who were Medicare beneficiaries,  $\geq 65$  years old, and had no cancer. Resident factors of interest included demographics and physical/cognitive impairment, and facility factors included US census region and structural characteristics (eg, bed size, ownership). Long-term opioid use was defined as  $\geq 90$  cumulative days of opioid use during a 120 day observation window - defined using fill dates and days'. Modified Poisson models were used to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) between resident/ facility-level characteristics and long-term opioid use.

**Results:** Nearly one third of long-stay residents used any opioid, with 14.5% using opioids long-term. Among long-term users, 35.3% received a long-acting opioid, with 17.1% receiving high ( $\geq 90$  mg/day oral morphine equivalents) daily doses. Hydrocodone (49.0%), tramadol (31.3%), and fentanyl (24.8%) were most commonly used. The prevalence of long-term use was higher in women (vs. men; aPR=1.20, 95% CI: 1.18-1.23) and those with no/mild cognitive impairment (vs. other; aPR=1.18, 95% CI: 1.16-1.20) or severe physical impairment (aPR=1.25; 95% CI: 1.22-1.27), and in government-owned nursing homes (vs. for-profit; aPR=1.10, 95% CI: 1.05-1.16). Long-term use varied by region (10.6% [Northeast] to 17.7% [Midwest]) and across facilities (median: 13.3% interquartile range: 6.7%-21.3%).

**Conclusions:** Long-term opioid use is substantially higher in nursing home residents than what has been previously reported in community-dwelling older adults. Further investigations of opioid safety in this frail population are needed.

**Contact:**

Jacob Hunnicutt, MPH  
PhD Candidate, Clinical and Population Health Research  
University of Massachusetts Medical School  
[Jacob.Hunnicutt@umassmed.edu](mailto:Jacob.Hunnicutt@umassmed.edu)